Not to sound negative, but what's the point? We're GIA, product is now available, and so what does presenting do? You know they're not going to reveal rx numbers. It will just end up leaving investors with more questions than answers.
It's a "general company update". They may update on ANCHOR sNDA and enrollment status of REDUCE-IT, distribution and covered lives, Coupon program (Vascepa Savings), might see pharmacokinetic data on combo pill, and some talk on future DTC push. There is a lot that they can potentially discuss.